Ovation Science Inc (TSE:OVAT)
:OVAT
Want to see TSE:OVAT full AI Analyst Report?
Top Page
Ovation Science
(OVAT)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.03
▼(-27.50% Downside)
Action:Downgraded
Date:05/08/26
The score is driven primarily by very weak financial performance (persistent losses, negative equity, and ongoing cash burn). Technicals also indicate weak momentum with price below longer-term moving averages and a negative MACD. Valuation provides limited support due to loss-making results (negative P/E) and no dividend yield data.
Positive Factors
Proprietary delivery platform
A proprietary transdermal platform provides a durable competitive edge: it supports differentiated finished products across cosmetic and therapeutic segments, creates higher switching costs versus commodity topical formulations, and can underpin licensing or co-development revenue over multiple product cycles.
Negative Factors
Negative shareholders' equity
Sustained negative equity signals accumulated losses exceeding capital, constraining financial flexibility. It limits borrowing options, can complicate supplier and partner relationships, and increases dilution or restructuring risk if the company must raise capital to continue operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery platform
A proprietary transdermal platform provides a durable competitive edge: it supports differentiated finished products across cosmetic and therapeutic segments, creates higher switching costs versus commodity topical formulations, and can underpin licensing or co-development revenue over multiple product cycles.
Read all positive factors
Ovation Science (OVAT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$881.12K
Dividend YieldN/A
Average Volume (3M)3.74K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth-40.03%
EPS Growth-31.85%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding35,244,682
10 Day Avg. Volume3,400
30 Day Avg. Volume3,744
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-0.98
Price to Sales (P/S)20.98
P/FCF Ratio-18.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ovation Science Business Overview & Revenue Model
Company Description
Ovation Science Inc. engages in the production of cannabis or hemp products in Canada, the United States, and Mexico. The company's Invisicare is a patented drug delivery technology for use in topical and transdermal skin care products containing ...
How the Company Makes Money
Ovation Science primarily makes money by selling finished topical products that incorporate its proprietary transdermal delivery technology, generating revenue from product sales through its commercial channels (e.g., direct-to-consumer and/or who...
Ovation Science Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 67.89K | 113.22K | 61.93K | 138.15K | 224.95K |
| Gross Profit | -312.45K | 85.72K | -251.43K | 134.11K | -168.75K |
| EBITDA | -598.18K | -404.15K | -778.83K | -786.73K | -2.39M |
| Net Income | -631.25K | -456.20K | -813.15K | -794.05K | -2.39M |
Balance Sheet | |||||
| Total Assets | 82.82K | 63.90K | 76.89K | 104.89K | 769.90K |
| Cash, Cash Equivalents and Short-Term Investments | 72.29K | 3.31K | 48.85K | 28.90K | 647.56K |
| Total Debt | 283.06K | 268.48K | 192.62K | 41.13K | 0.00 |
| Total Liabilities | 1.54M | 1.15M | 728.99K | 187.84K | 63.74K |
| Stockholders Equity | -1.46M | -1.09M | -652.10K | -82.95K | 706.15K |
Cash Flow | |||||
| Free Cash Flow | -76.44K | -178.82K | -336.02K | -670.80K | -885.75K |
| Operating Cash Flow | -76.44K | -178.82K | -336.02K | -670.80K | -885.75K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M |
| Financing Cash Flow | 146.48K | 133.28K | 356.16K | 47.24K | 0.00 |
Ovation Science Technical Analysis
Neutral
0.04
Price Trends
0.03
Positive
0.03
Negative
0.04
Negative
Market Momentum
<0.01
Negative
58.79
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OVAT, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.79 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:OVAT.
Ovation Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$9.29M | 8.94 | 11.57% | ― | -6.27% | 61.54% | |
56 Neutral | C$33.99M | -8.58 | -19.10% | ― | 0.66% | -14.29% | |
55 Neutral | C$66.63M | -0.80 | -21.73% | ― | 45.36% | 17.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$66.92M | -10.33 | -19.76% | ― | -100.00% | 87.93% | |
41 Neutral | C$51.16M | -10.76 | ― | ― | -62.34% | 9.80% | |
40 Underperform | C$881.12K | -2.26 | 33.19% | ― | -40.03% | -31.85% |
* Healthcare Sector Average
TSE:OVAT
Ovation Science
0.03
>-0.01
-16.67%
TSE:ATLE
Willow Biosciences Inc
0.19
>-0.01
-4.52%
TSE:LABS
MediPharm Labs
0.08
<0.01
14.29%
TSE:OILS
Nextleaf Solutions
0.06
>-0.01
-8.33%
TSE:VEXT
Vext Science
0.28
0.17
150.00%
TSE:BNXT
BioNxt Solutions
0.42
-0.12
-22.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.